Biohaven (BHVN) Financials

Biohaven (NYSE: BHVN) has shown a pattern of ongoing net losses and cash burn from operations over the past several quarters, but has also featured notable liquidity infusions from financing activities. The latest data (Q4 2025) illustrate a significant financing boost that helped offset operating cash burn for the quarter. Here are the key takeaways and trends drawn from the last four years of quarterly statements.

• Significant equity financing in 2025Q4: Issuance of Common Equity recorded at about $191.0 million, contributing to cash reserves.
• Strong financing inflows in 2025Q4: Net Cash From Financing Activities was about $188.8 million, boosting liquidity despite ongoing cash burn in operations.
• Substantial equity financing in 2024Q4: Issuance of Common Equity was about $495.97 million, providing a sizable cash cushion that supported operations and investments in that period.
• Non-cash adjustments and depreciation: Depreciation + amortization and non-cash adjustments provided modest incremental non-cash support to reported income (e.g., non-cash adjustments to reconcile net income, plus depreciation in various quarters).
• Liquidity buildup in recent quarters: Cash & Equivalents rose from mid-2024 levels to the mid- to high-100 million range by 2025Q3 (e.g., about $184.8 million in 2025Q3), providing a stronger liquidity position than mid-2024.
• Investing activity variability: Sale/maturity of investments contributed notable cash inflows in some quarters (e.g., about $165.0 million in 2025Q3 and about $75.0 million in 2025Q4), but overall net cash from investing activities remained negative in several quarters due to other investing outflows.
• Revenue status: Total Revenue remains minimal or zero in several periods, with the bulk of results driven by operating expenses rather than product revenue in multiple quarters.
• Per-share and earnings picture: Net income per share metrics reflect meaningful losses (e.g., 2025Q4 Basic and Diluted EPS around -$1.11, and cumulative losses in other quarters), indicating ongoing profitability challenges despite liquidity supports.
• Ongoing operating cash burn: Net Cash From Continuing Operating Activities was consistently negative across the latest quarters (e.g., about -$130.7 million in 2025Q4, and substantial negatives in 2025Q3, 2025Q2, and 2025Q1), underscoring a continuing cash burn from core operations.

Additional context and trends to keep in mind:

From 2022 through 2025, Biohaven has reported large net losses on a continuing operations basis, with quarterly net income figures often deep in the red. The cash flow from operations has typically been negative, indicating that operating activities did not generate enough cash to cover expenses in those periods. The company has relied on financing activities (primarily equity issuances) to fund its cash shortfall, with notable equity raises in 2024 and 2025 demonstrated by the large issuance numbers described above. Net cash from investing activities has shown variability, including sizeable inflows from the sale/maturity of investments in some quarters, but overall investing cash flows have not consistently offset the operating cash burn.

On the balance sheet side, total assets have fluctuated with cash and investments, and total liabilities have remained substantial. In recent quarters, there are signs of improving liquidity due to financing inflows, but some periods show pressure on shareholders’ equity (including instances of negative total equity in certain quarters), reflecting the net effect of sustained losses and large share issuances. The company’s dependence on frequent financing activity creates dilution risk for existing holders, even as it adds near-term liquidity.

Bottom line for retail investors:

• Near-term liquidity improved in late 2024 and again in 2025 thanks to sizable equity issuances and financing inflows, which helped fund ongoing operations and investing activities.
• Operating cash flow remains negative in most quarters, indicating the business has not yet achieved positive cash generation from core operations.
• Persistent net losses and, in some cases, negative equity suggest continued downside risk unless there is a clear path to profitability or additional financing terms that do not overly dilute existing shareholders.
• Investing activity has been volatile, with occasional inflows from investment sales that provide liquidity, but overall investing cash flows do not consistently offset operating deficits.
• If you’re evaluating BHVN as a potential investment, keep an eye on updated quarterly results for signs of improving operating margins, an actual revenue ramp, or new funding strategies that reduce dilution risk.